BSE: 543963 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Shelter Pharma Ltd is a below average quality company.
The key valuation ratios of Shelter Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Shelter Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0.3% | 0.7% | 0.9% | 1.2% | 1.3% | 1.8% | 1.3% | 36.2% | 59.6% | 33.6% | - |
| Value Creation Index ⓘ | -1.0 | -1.0 | -0.9 | -0.9 | -0.9 | -0.9 | -0.9 | 1.6 | 3.3 | 1.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 25.1 | 28.1 | 30 | 31.5 | 27.7 | 30.1 | 22.5 | 30.1 | 36.2 | 40 | 40 |
| Sales YoY Gr. | - | 12.3% | 6.7% | 4.8% | -11.9% | 8.4% | -25.2% | 33.7% | 20.3% | 10.7% | - |
| Adj EPS ⓘ | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 2.4 | 7.5 | 5.4 | 5.4 |
| YoY Gr. | - | 100% | 16.7% | 0% | 14.3% | 37.5% | -45.5% | 3850% | 217.7% | -28.8% | - |
| BVPS (₹) ⓘ | 8.8 | 8.7 | 8.8 | 8.5 | 8.6 | 8.2 | 8 | 10.3 | 17.6 | 30.2 | 30.2 |
| Adj Net Profit ⓘ | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 1.8 | 5.8 | 6.2 | 6 |
| Cash Flow from Ops. ⓘ | 0 | 0 | -0.2 | 0.4 | 0 | -0.3 | -0.3 | 0.5 | -1 | -1.9 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | -0.5 | 0.2 | 0 | -0.9 | -0 | 0.3 | -1.9 | -0.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.3% | 7.6% | 21.2% | 10.7% | ||||
| Adj EPS ⓘ | 77.9% | 131.9% | 347% | -28.8% | ||||
| BVPSⓘ | 14.7% | 28.4% | 55.9% | 71.7% | ||||
| Share Price | - | - | - | -9.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.2 | 0.6 | 0.6 | 0.7 | 0.8 | 1.1 | 0.6 | 22.9 | 49.7 | 24.6 | 17.8 |
| Op. Profit Mgn % ⓘ | 0.4 | 0.6 | -2.3 | 0.5 | 0.7 | 0.8 | 0.9 | 9.1 | 22.3 | 22 | NAN |
| Net Profit Mgn % ⓘ | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 6.1 | 16.1 | 15.5 | 15.5 |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | - |
| Working Cap Days ⓘ | 155 | 112 | 106 | 97 | 105 | 97 | 127 | 107 | 144 | 215 | 0 |
| Cash Conv. Cycle ⓘ | 102 | 67 | 62 | 53 | 54 | 52 | 74 | 69 | 113 | 152 | 0 |
Sales growth is growing at healthy rate in last 3 years 21.20%
Net Profit is growing at healthy rate in last 3 years 347.03%
Return on Equity has declined versus last 3 years average to 17.80%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.4 | - |
| TTM Sales (₹ Cr.) | 40 | - |
| BVPS (₹.) ⓘ | 30.2 | - |
| Reserves (₹ Cr.) ⓘ | 23 | - |
| P/BV ⓘ | 1.74 | - |
| PE ⓘ | 9.76 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 41.10 / 80.90 |
| All Time Low / High (₹) | 37.50 / 80.90 |
| Market Cap (₹ Cr.) | 60.5 |
| Equity (₹ Cr.) | 11.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.7 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.06 | 28.14 | 30.01 | 31.46 | 27.73 | 30.07 | 22.48 | 30.06 | 36.15 | 40.02 |
| Operating Expenses ⓘ | 24.96 | 27.98 | 30.70 | 31.30 | 27.55 | 29.82 | 22.29 | 27.32 | 28.09 | 31.24 |
| Manufacturing Costs | 0.33 | 0.21 | 0.40 | 0.47 | 0.42 | 0.32 | 0.21 | 0.21 | 0.33 | 0.31 |
| Material Costs | 22.29 | 26.34 | 28.73 | 29.22 | 25.70 | 28.30 | 21.14 | 25.85 | 26.25 | 28.92 |
| Employee Cost | 0.28 | 0.43 | 0.47 | 0.52 | 0.39 | 0.39 | 0.33 | 0.35 | 0.45 | 0.63 |
| Other Costs ⓘ | 2.05 | 1.02 | 1.09 | 1.09 | 1.04 | 0.82 | 0.62 | 0.91 | 1.05 | 1.38 |
| Operating Profit ⓘ | 0.09 | 0.16 | -0.69 | 0.16 | 0.18 | 0.24 | 0.19 | 2.74 | 8.07 | 8.79 |
| Operating Profit Margin (%) | 0.4% | 0.6% | -2.3% | 0.5% | 0.7% | 0.8% | 0.8% | 9.1% | 22.3% | 22.0% |
| Other Income ⓘ | 0.03 | 0 | 0.83 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0 | 0.01 |
| Interest ⓘ | 0 | 0.01 | 0.01 | 0 | 0 | 0.01 | 0.02 | 0.08 | 0.03 | 0.26 |
| Depreciation ⓘ | 0.09 | 0.10 | 0.07 | 0.10 | 0.12 | 0.13 | 0.12 | 0.17 | 0.16 | 0.25 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.90 | 0 |
| Profit Before Tax ⓘ | 0.02 | 0.05 | 0.06 | 0.07 | 0.08 | 0.11 | 0.06 | 2.51 | 6.98 | 8.28 |
| Tax ⓘ | 0 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 | 0.67 | 1.78 | 2.08 |
| Profit After Tax | 0.02 | 0.05 | 0.05 | 0.05 | 0.06 | 0.08 | 0.04 | 1.84 | 5.21 | 6.20 |
| PAT Margin (%) | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.2% | 6.1% | 14.4% | 15.5% |
| Adjusted EPS (₹) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 2.4 | 6.7 | 5.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 7.77 | 7.77 | 7.78 | 7.63 | 7.69 | 6.98 | 7.11 | 8.93 | 14.55 | 35.82 |
| Share Capital ⓘ | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.48 | 0.48 | 7.74 | 11.56 |
| Reserves ⓘ | 7.32 | 7.31 | 7.32 | 7.17 | 7.23 | 6.53 | 6.63 | 8.44 | 6.81 | 24.26 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 2.07 | 2.07 | 0.11 | 0.07 | 0.16 | 0.24 | 0 | 0.10 | 1.78 | 0.58 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.06 | 0.48 | 0.57 |
| Short Term Debt | 2.07 | 2.07 | 0.11 | 0.07 | 0.16 | 0.24 | 0 | 0.04 | 1.30 | 0 |
| Trade Payables | 0.15 | 0.18 | 0.17 | 0.15 | 0.19 | 0.26 | 0.31 | 0.32 | 0.47 | 0.71 |
| Others Liabilities ⓘ | 1.34 | 1.53 | 3.58 | 2.96 | 2.97 | 3.15 | 2.77 | 3.49 | 4.65 | 0.77 |
| Total Liabilities ⓘ | 11.34 | 11.56 | 11.64 | 10.81 | 11 | 10.63 | 10.20 | 12.84 | 21.45 | 37.88 |
Fixed Assets | ||||||||||
| Gross Block | 3.14 | 3.28 | 3.31 | 3.37 | 3.51 | 3.11 | 3.12 | 3.17 | 3.72 | 5.70 |
| Accumulated Depreciation | 0.43 | 0.67 | 0.60 | 0.70 | 0.82 | 1.34 | 1.55 | 1.72 | 1.88 | 2.13 |
| Net Fixed Assetsⓘ | 2.71 | 2.61 | 2.71 | 2.67 | 2.69 | 1.77 | 1.57 | 1.45 | 1.85 | 3.58 |
| CWIP ⓘ | 0 | 0.14 | 0.11 | 0.13 | 0.22 | 0 | 0 | 0.55 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 |
| Inventories | 4.09 | 4.43 | 3.91 | 3.81 | 4.12 | 4.31 | 4.02 | 5.67 | 7.96 | 9.93 |
| Trade Receivables | 1.15 | 1 | 1.16 | 0.59 | 0.06 | 0.61 | 0.76 | 1.61 | 8.19 | 8.85 |
| Cash Equivalents | 0.11 | 0.10 | 0.08 | 0.08 | 0.12 | 0.14 | 0.37 | 0.10 | 0.43 | 5.04 |
| Others Assetsⓘ | 3.28 | 3.28 | 3.67 | 3.53 | 3.78 | 3.13 | 2.81 | 2.78 | 2.34 | 9.80 |
| Total Assets ⓘ | 11.34 | 11.56 | 11.64 | 10.81 | 11 | 10.63 | 10.20 | 12.84 | 21.45 | 37.88 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 0 | -0.23 | 0.37 | 0 | -0.27 | -0.28 | 0.52 | -0.96 | -1.85 |
| PBT ⓘ | 0 | 0 | 0.06 | 0.07 | 0 | 0.11 | 0.06 | 2.51 | 7.05 | 8.40 |
| Adjustment ⓘ | 0 | 0 | 0.07 | 0.10 | 0 | -0.18 | -0.18 | 0.05 | 0.17 | 0.58 |
| Changes in Working Capital ⓘ | 0 | 0 | -0.33 | 0.37 | 0 | -0.2 | -0.17 | -2.04 | -8.19 | -9.26 |
| Tax Paid ⓘ | 0 | 0 | -0.03 | -0.16 | 0 | 0 | 0 | 0 | 0 | -1.57 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | -0.33 | -0.34 | 0 | 0.29 | 0.03 | -0.85 | 0.11 | -4.54 |
| Capex | 0 | 0 | -0.13 | -0.28 | 0 | -0.05 | -0.01 | -0.60 | 0 | -0.85 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -0.20 | -0.06 | 0 | 0.34 | 0.04 | -0.25 | 0.12 | -3.69 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0.54 | -0.04 | 0 | 0 | 0.48 | 0.06 | 1.18 | 11.01 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0.48 | 0 | -0.20 | 10.91 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0.54 | -0.04 | 0 | 0 | 0 | 0.06 | 0.48 | 0.09 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.90 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | -0.02 | 0 | 0 | 0.02 | 0.23 | -0.27 | 0.33 | 4.61 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 0.26 | 0.74 | 0.75 | 0.87 | 0.96 | 1.31 | 0.68 | 25.95 | 48.22 | 25.58 |
| ROCE (%) | 0.28 | 0.71 | 0.9 | 1.16 | 1.33 | 1.84 | 1.29 | 36.17 | 59.61 | 33.62 |
| Asset Turnover Ratio | 1.86 | 2.46 | 2.59 | 2.8 | 2.54 | 2.78 | 2.16 | 2.61 | 2.11 | 1.35 |
| PAT to CFO Conversion(x) | 0 | 0 | -4.6 | 7.4 | 0 | -3.38 | -7 | 0.28 | -0.18 | -0.3 | Working Capital Days |
| Receivable Days | 40 | 14 | 13 | 10 | 4 | 4 | 11 | 14 | 49 | 78 |
| Inventory Days | 68 | 55 | 51 | 45 | 52 | 51 | 68 | 59 | 69 | 82 |
| Payable Days | 6 | 2 | 2 | 2 | 2 | 3 | 5 | 4 | 5 | 7 |
The company was originally converted from a Partnership Firm 'M/s Shelter Pharma' to a Public Limited Company on October 12, 2007 as 'Shelter Pharma Limited' under the provisions of the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Havelli.
The company primarily focuses in manufacturing herbal products with well-built presence in Human Pharma as well as Veterinary space. Shelter started with a few products about decades back. However, over a period of time, it has added products to its portfolio through its in-house R & D efforts backed by sound knowledge of Ayurveda. Shelter is present in most of non-critical segment of Human as well as Veterinary Pharma through its well spread portfolio. It enjoys a good product acceptance and market share in the state of Gujarat. In the Human pharma segment, Shelter has product portfolio of OTC products as well Ethical pharma products. Similarly, Shelter has OTC and Ethical presence in Veterinary segment. Shelter has a respectable track record of efficacy of its products. All the products are priced very competitively considering Shelter’s target market.
Shelter Pharma originally named as Shelter Pharmacy, it was converted to Shelter Pharma Limited on October 12, 2007 under Part IX of The Companies Act, 1956. The company is being promoted by Mr Mustaqim Nisarahmed Sabugar and Mr Shakil Nisarahmed Sabugar. Promoters have nurtured and strengthened the business over the years. The business was slowly expanded from local presence in Himmatnagar to well spread presence in the state of Gujarat. Shelter remained a family enterprise before incorporation of the Company with a consolidated position in Gujarat. Introduction of new generation of promoters, set up of new companies around 2007 brought new ideas and aspirations to the business. Shelter has embarked on a major restructuring drive in line with redefined goals. The company has reworked its organizational structure, product portfolio, distribution network, pricing, packaging and internal processes. It has also invested substantially in strengthening infrastructure with fresh fund infusion to improve its manufacturing capacity in Himmatnagar. Shelter sources required raw material from nearby villages. Its raw material is sourced directly from farmers. Company has long established relationships with farmers, giving it an assured supply of herbs and plants. Shelter focuses on rural/semi urban market as its clientele to offer high quality price competitive remedies to villages.
Business area of the company
The company is engaged in the business of manufacturing herbal products with well-built presence in Human Pharma as well as Veterinary.
Products of the company
Human healthcare
Veterinary healthcare
History and milestone
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Inatant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
